A resolution expressing the sense of the Senate that the scientific judgement of the Food and Drug Administration that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable and based on science.

1/24/2024, 10:15 PM

Summary of Bill SRES 510

Bill 118 sres 510 is a resolution introduced in the US Senate that aims to express the Senate's support for the scientific judgement of the Food and Drug Administration (FDA) regarding the safety and effectiveness of mifepristone, a medication used for medication abortion. The resolution emphasizes the importance of respecting the FDA's expertise and decisions in determining the safety and efficacy of medications.

Additionally, the resolution calls for laws and policies governing access to medication abortion care in the United States to be equitable and based on scientific evidence. It highlights the importance of ensuring that individuals have timely access to lifesaving medication abortion care, and that restrictions on access to this care should be based on scientific evidence rather than political ideology.

Overall, Bill 118 sres 510 seeks to promote a fair and science-based approach to regulating access to medication abortion care in the United States, emphasizing the importance of respecting the FDA's scientific judgement and ensuring equitable access to this important healthcare service.

Congressional Summary of SRES 510

This resolution expresses the sense of the Senate that (1) policies governing access to medication abortion care should be based on scientific review by the Food and Drug Administration (FDA), and (2) the FDA has found mifepristone to be safe and effective for women seeking abortions.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill SRES 510

Bill SRES 510 is currently in the status of Bill Introduced since December 14, 2023. Bill SRES 510 was introduced during Congress 118 and was introduced to the Senate on December 14, 2023. Bill SRES 510's most recent activity was Referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S6003-6004) as of December 14, 2023

Bipartisan Support of Bill SRES 510

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill SRES 510

Primary Policy Focus

Health

Alternate Title(s) of Bill SRES 510

A resolution expressing the sense of the Senate that the scientific judgement of the Food and Drug Administration that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable and based on science.A resolution expressing the sense of the Senate that the scientific judgement of the Food and Drug Administration that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable and based on science.

Start holding our government accountable!